Cytosorbents (CTSO) Net Cash Flow (2010 - 2026)

Cytosorbents has reported Net Cash Flow for 17 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 136.41% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$8.0 million (down 359.99% YoY), and the FY2025 full-year result was -$3.5 million, up 39.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$1.2 million, up from -$2.6 million in the prior quarter.
• The five-year high for Net Cash Flow was $5.7 million in Q4 2023, with the low at -$12.7 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$2.8 million across 5 years, with a median of -$2.6 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 340.15% — and 2023, when it jumped 1137.17%.
• Cytosorbents' Net Cash Flow stood at -$546406.0 in 2022, then jumped by 1137.17% to $5.7 million in 2023, then tumbled by 140.55% to -$2.3 million in 2024, then dropped by 14.8% to -$2.6 million in 2025, then surged by 54.21% to -$1.2 million in 2026.
• The last three Net Cash Flow figures came in at -$1.2 million (Q1 2026), -$2.6 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.